Lexicon Pharmaceuticals | LXRX - Stock


Lexicon Pharmaceuticals reported $276K in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Abbott USD 6.99B 501M Mar/2026
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Akebia Therapeutics USD 13.02M 22K Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
AstraZeneca USD 6.93B 362M Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Coherus Biosciences USD 5.67M 842K Jun/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Halozyme Therapeutics USD 137.14M 18.33M Jun/2026
Illumina USD 629M 18M Jun/2026
Insmed USD 142.38M 9.48M Jun/2026
J&J USD 15.14B 561M Jun/2026
Lexicon Pharmaceuticals USD 276K 5K Mar/2026
MacroGenics USD 9.5M 1.59M Mar/2026
MannKind USD 44.42M 4.75M Jun/2026
Merck USD 6.21B 272M Jun/2026
Moderna USD 280M 134M Jun/2026
Novartis USD 6.22B 66M Jun/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Thermo Fisher Scientific USD 5.5B 71M Mar/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
United Therapeutics USD 193.8M 15.5M Jun/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025